Diabetes drug 'Actos' to be pulled from market because of risk of bladder cancer
Published: 2011-06-15 06:56:00
Updated: 2011-06-15 06:56:00
Japanese pharmaceutical company Takeda’s blockbuster anti-diabetes pill “Actos (pioglitazone)” faces being banned in the Korean market as the Korea Food and Drug Administration (KFDA) on Monday ordered doctors to refrain from prescribing it for type-2 diabetes patients due to bladder cancer risk....
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.